<< Back to Blog

Orfan Biotech, a company dedicated to developing small molecules for the treatment of Primary Hyperoxaluria

O2h Update: “Orfan Biotech, a company dedicated to developing small molecules for the treatment of Primary Hyperoxaluria. Orfan has a collaboration with O2h involving financial and medicinal chemistry support. Hans Maag, Med Chemist, Orfan, “We are very thankful to the research partnership with O2h which is allowing Orfan to efficiently and effectively drive our Medicinal Chemistry programs. This partnership demonstrates the power of bringing together insights generated by the Orfan founders with state-of-the art drug discovery and chemistry expertise built in collaboration with the O2h”

Posted by

Leave a Reply